TLR9 and prostate carcinoma: Previous studies also showed that treatment of TLR9-expressing prostate cancer cells with synthetic TLR9-ligands, which mimic the structure of bacterial DNA, stimulates the invasion by increasing the matrix metalloproteinase activity in vitro [15, 16].